SCM
PACB icon

Segantii Capital Management’s Pacific Biosciences PACB Stock Holding History

Segantii Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-636,121
Closed -$2.19M – 71
2020
Q2 		$2.19M Hold
636,121
– – 0.15% 48
2020
Q1 		$1.95M Buy
636,121
+238,826
+60% +$978K 0.16% 47
2019
Q4 		$2.04M Buy
+397,295
New +$2.02M 0.15% 66

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Segantii Capital Management's PACB Position: Q3 2020 in Review

Segantii Capital Management sold out of Pacific Biosciences (PACB) in Q3 2020, closing a stake of 636,121 shares — an estimated $2.19M sold.

Segantii Capital Management first reported a position in PACB in Q4 2019 and held it in 3 quarters. The position peaked at $2.19M in Q2 2020. 174 funds tracked by Wall St. Rank hold PACB as of Q3 2020.

  • Segantii Capital Management reported no remaining Pacific Biosciences position as of Q3 2020 after selling out during the quarter.
  • Segantii Capital Management sold 636,121 Pacific Biosciences shares in Q3 2020, an estimated $2.19M.
  • Segantii Capital Management first reported a position in Pacific Biosciences in Q4 2019 and held it in 3 quarters.
  • Segantii Capital Management's Pacific Biosciences position peaked at $2.19M in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2020.

Based on Segantii Capital Management's 13F filing for Q3 2020, filed 10 Nov 2020.